Sample Size Issues in the Design of Clinical Trials
Monday 2 June, 10:20--12:10
- Organizer: Jackie HAN
- Bristol-Myers Squibb
- Moderator: Jackie HAN
- Bristol-Myers Squibb
- David R. BRISTOL
- Schering-Plough Research Institute, Kenilworth, NJ, USA
Until recently, hypothesis testing using multiple comparison
procedures (MCPs) has required extensive tables of critical values.
The function PROBMC of SAS (1992) provides a solution to the problem
of providing p-values for various MCPs; namely, Dunnett's procedure
for comparison with a control, the Studentized Range Test, and the
Studentized Maximum Modulus
Test. The problem of computing the power of these test procedures and
the corresponding problem of sample size determination to control the
power have not been adequately addressed. In some cases, PROBMC can be
used to evaluate the power; some simple numerical methods are
presented for use in other situations. Some simulation results are
presented to examine the adequacy of the approximations.
[David R. Bristol, Schering-Plough Research Institute, Kenilworth, NJ 07033]
- Weichung Joe SHIH
- Merck Research Laboratories, Rahway, NJ, USA
Sample size re-estimation for clinical trials is a type of interim
analysis with a purpose differing from that of the familiar group
sequential methods. In this talk I will introduce the rationale,
methods, and issues for two common cases: normal and binary outcome
variables. Current regulatory guidelines for statistical design and
analysis regarding the sample size re-estimation in new drug
applications will also be discussed.
[Weichung Joe Shih, Merck Research Laboratories]
- Hongjie Zheng, Ph.D
- Novartis Pharmaceuticals, Summit, NJ, USA
Sample size calculation for clinical trials is routine for
statisticians working in the pharmaceutical industry. Often
statisticians calculate sample size either by hand or by writing their
own little computer programs. Since sample size calculation is so
important in determining the cost of the trial as well as in
demonstrating the efficacy of a new drug when the new drug is indeed
efficacious, a well validated sample size software will be a useful
tool to aid the statisticians in their calculation. In this talk, I
will review the top
two ranked commercial software PASS 6.0 and nQuery Advisor in terms of
their capacity for sample size calculation in clinical trials. Both
statistical procedures and their accuracy of the packages considered
will be examined, but focus will be on the usefulness of the software
in clinical trials.
[Hongjie Zheng, Ph.D, Department of Biostatistics, Novartis Pharmaceuticals, Summit, NJ 07901]
Back to JRC program
Back to JRC Home Page